Clinical trials: Essential,Hypertension
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT07421414
- Testing
- BR1015-A, BR1015-3, BR1015-2
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Untreated Hypertension, Healthy Volunteers
Comparison of Ultrafast Echo With Echotracking
The aim is to compare a new technique for assessing mechanical properties of large arteries: the Ultrafast echo with the reference technique, the echotracking.
- Trial name
- NCT01743352
- Where
- France
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- French Cardiology Society
Essential Hypertension
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately…
- Trial name
- NCT06416865
- Testing
- AJU-C52L, AJU-C52, C52R1L, C52R1M
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- AJU Pharm Co., Ltd.
Essential Hypertension, Hepatic Impairment
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers
To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers
- Trial name
- NCT01146938
- Testing
- fimasartan
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension Essential, Salt Excess
Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant
The study is a non-pharmacological interventional, single-center, national, non-randomised, comparative and open label.
- Conditions
- Hypertension Essential, Salt Excess, Genetic Hypertension
- Trial name
- ADD-AMI (NCT06416735)
- Testing
- Amiloride
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Ospedale San Raffaele
Essential Hypertension
Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension
- Trial name
- NCT04488978
- Testing
- Irbesartan/Amlodipine
- Where
- South Korea
- Volunteers
- 440 people
- Sponsor
- Handok Inc.
Isolated Systolic Hypertension
Systolic Hypertension in Europe Placebo-Controlled Trial
The Syst-Eur Trial is a concerted action of the European Community's Medical and Health Research Programme. The trial is carried out in consultation with the World Health Organization, the International Society of Hypertension…
- Trial name
- Syst-Eur (NCT02088450)
- Testing
- Active treatment with nitrendipine (10-40 mg/day).
- Volunteers
- 4,695 people
- Sponsor
- KU Leuven
Hypertension, Vascular Diseases
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE-II (NCT03614260)
- Testing
- Paradise Renal Denervation System, Renal Angiogram
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- ReCor Medical, Inc.
Hypertension
Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension
The primary objective of this study is to investigate incremental cost effectiveness of Nifedipine CR and Amlodipine in combination therapy with Valsartan for the treatment of essential hypertensive patients.
- Trial name
- NCT01518855
- Testing
- Nifedipine (Adalat, BAYA1040), Amlodipine (Norvasc), Diovan
- Where
- 4 sites in Japan
- Volunteers
- 514 people
- Sponsor
- Bayer
Isolated Systolic Hypertension
Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension
1. Study name: Blood Pressure and Lipids Reduction in High Risk Elderly Patients with Isolated Systolic Hypertension. 2. Medicine: amlodipine/atorvastatin tablet (5mg/10mg) and amlodipine (5mg). 3.
- Trial name
- NCT05165251
- Testing
- Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET, Amlodipine 5mg, Lifestyle intervention
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hypertension
Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension
This prospective chronotherapy trial will investigate the potential differing efficacy of ramipril in doses from 5 to 10 mg/day when administered, as a monotherapy either upon awakening from nighttime sleep or at bedtime, to…
- Trial name
- HYCCRA (NCT00473174)
- Testing
- Ramipril, ambulatory blood pressure monitoring
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- University of Vigo
Hypertension
Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide
This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension
- Trial name
- NCT00796159
- Testing
- Olmesartan medoxomil
- Volunteers
- 1,723 people
- Sponsor
- Pfizer
Essential Hypertension
Study of CS-3150 in Patients With Essential Hypertension
To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.
- Trial name
- ESAX-HTN (NCT02890173)
- Testing
- CS-3150, Eplerenone
- Where
- Japan
- Volunteers
- 1,001 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
- Trial name
- NCT01785472
- Testing
- LCZ696, Olmesartan
- Where
- 50 sites in China, Hong Kong and 5 more
- Volunteers
- 1,438 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
The purpose of this study is to compare depressor effect and safety between combination therapy with telmisartan plus low-dose hydrochlorothiazide and amlodipine in hypertensive patients.
- Trial name
- ONEAST (NCT00509470)
- Testing
- telmisartan plus hydrochlorothiazide, Amlodipine
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Tokyo University
Hypertension, High Blood Pressure
A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension
To evaluate the safety and effectiveness of the ROX Coupler used to create an arteriovenous anastomosis in the iliac region (between the iliac artery and vein) in subjects with hypertension.
- Trial name
- CONTROL HTN-2 (NCT02895386)
- Testing
- ROX Coupler
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- ROX Medical, Inc.